AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18669454 — intervention group
Group type: EXPERIMENTAL
Intervention: GemCap
Number of subjects: 319
Study 18669454 — intervention group
Group type: COMPARATOR
Intervention: Gem
Number of subjects: 319
Study 18669454 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 319
Study 15961625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate intervention
Number of subjects: 376
Study 15961625 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional intervention
Number of subjects: 376
Study 15961625 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 376
Study 14569386 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid induced Fluorescence diagnosis (FD)
Number of subjects: 191
Study 14569386 — intervention group
Group type: COMPARATOR
Intervention: Conventional white light (WL)
Number of subjects: 191
Study 10394994 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg oral m-CPP
Number of subjects: 12
Study 10394994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8588419 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH (8 IU/day)
Number of subjects: 48
Study 8588419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1896809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 71
Study 1896809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 6350243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed beam radiation therapy
Number of subjects: 199
Study 6350243 — intervention group
Group type: COMPARATOR
Intervention: Photon control treatment
Number of subjects: 199
Study 31012124 — intervention group
Group type: EXPERIMENTAL
Intervention: National early warning score observation protocol
Number of subjects: 60956
Study 31012124 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60956
Study 29176402 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day hydrocortisone
Number of subjects: 80
Study 29176402 — intervention group
Group type: COMPARATOR
Intervention: 200 mg/day hydrocortisone
Number of subjects: 80
Study 26335669 — intervention group
Group type: EXPERIMENTAL
Intervention: Kineflex‐L
Number of subjects: 204
Study 26335669 — intervention group
Group type: COMPARATOR
Intervention: CHARITÉ
Number of subjects: 204
Study 26335669 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 204
Study 26335669 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ion analysis (Kineflex‐L subgroup)
Number of subjects: 204
Study 24662499 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 90
Study 24662499 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 90
Study 24662499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22717245 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 122
Study 22717245 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 122
Study 20153030 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose extract (4.8 microg Amb a 1/d)
Number of subjects: 115
Study 20153030 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose extract (48 microg Amb a 1/d)
Number of subjects: 115
Study 20153030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 18589036 — intervention group
Group type: EXPERIMENTAL
Intervention: 500‐mL water preload
Number of subjects: 24
Study 18589036 — intervention group
Group type: COMPARATOR
Intervention: No preload
Number of subjects: 24
Study 15947768 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion with oral anticoagulation
Number of subjects: 127
Study 15947768 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with an event
Number of subjects: 127
Study 11952008 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides lipid emulsion
Number of subjects: 20
Study 11952008 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglycerides lipid emulsion
Number of subjects: 20
Study 10805055 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day for 3 months)
Number of subjects: 11
Study 10805055 — intervention group
Group type: COMPARATOR
Intervention: Control (age- and gender-matched individuals)
Number of subjects: 11
Study 8651963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) at 3 mg/kg/day
Number of subjects: 361
Study 8651963 — intervention group
Group type: COMPARATOR
Intervention: DMARDs
Number of subjects: 361
Study 1299483 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm of tribasic sodium phosphate four times daily for 3 days
Number of subjects: 6
Study 1299483 — intervention group
Group type: COMPARATOR
Intervention: Glucose placebo four times daily for 3 days
Number of subjects: 6
Study 6389582 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 102
Study 31085979 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplementation for 4 weeks
Number of subjects: 28
Study 31085979 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation for 4 weeks (glucose and energy-matched)
Number of subjects: 28
Study 31085979 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency cherry (MC) supplementation
Number of subjects: 28
Study 31085979 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 28
Study 31085979 — intervention group
Group type: COMPARATOR
Intervention: Montmorency cherry (MC) and placebo supplementation
Number of subjects: 28
Study 29122600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 52
Study 29122600 — intervention group
Group type: COMPARATOR
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 52
Study 27494570 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 8 (average levonorgestrel release rate approximately 8 μg/24 h over the first year, total content 13.5 mg)
Number of subjects: 560
Study 27494570 — intervention group
Group type: COMPARATOR
Intervention: EE/DRSP (30 μg ethinyl estradiol/3 mg drospirenone)
Number of subjects: 560
Study 25037251 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) - sensor-On arm
Number of subjects: 153
Study 25037251 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucose monitoring (CGM) - sensor-Off arm
Number of subjects: 153
Study 22101499 — intervention group
Group type: EXPERIMENTAL
Intervention: SEHB
Number of subjects: 94
Study 22101499 — intervention group
Group type: COMPARATOR
Intervention: BT only
Number of subjects: 94
Study 19995925 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir-based highly active antiretroviral therapy (HAART)
Number of subjects: 10
Study 17599884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aortic cross clamping (IACC)
Number of subjects: 345
Study 17599884 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic cardioplegic solution (HCS)
Number of subjects: 345
Study 16239366 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium (25 mg)
Number of subjects: 7
Study 16239366 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril erbumine (2 mg)
Number of subjects: 7
Study 16239366 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 7
Study 12033660 — intervention group
Group type: EXPERIMENTAL
Intervention: GP desktop resource (GDR)
Number of subjects: 107
Study 12033660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 12146713 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracilaria verrucosa (from Marseille)
Number of subjects: 18
Study 12146713 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria hyperborea (from Marseille)
Number of subjects: 18
Study 12146713 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracilaria verrucosa (from Brussels)
Number of subjects: 18
Study 12146713 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria hyperborea (from Brussels)
Number of subjects: 18
Study 12146713 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracilaria verrucosa (comparison between Brussels and Marseille)
Number of subjects: 18
Study 12146713 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria hyperborea (comparison between Brussels and Marseille)
Number of subjects: 18
Study 12146713 — intervention group
Group type: COMPARATOR
Intervention: Potassium iodide (control)
Number of subjects: 18
Study 12146713 — intervention group
Group type: COMPARATOR
Intervention: Monoiodotyrosine (control)
Number of subjects: 18
Study 9830251 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed group
Number of subjects: 0
Study 9830251 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 7926346 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 29
Study 7926346 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 29
Study 2668129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of SMS 201-995 at 25 micrograms/h
Number of subjects: 6
Study 2668129 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of SMS 201-995 at 50 micrograms every 12 hours
Number of subjects: 6
Study 2668129 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous SMS 201-995 administered by patients at home during open follow-up study
Number of subjects: 6
Study 175314 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 38
Study 175314 — intervention group
Group type: COMPARATOR
Intervention: No steroids (control group)
Number of subjects: 38
Study 7240437 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (975 mg administered four times a day, total daily dose 3.9 Gm)
Number of subjects: 16
Study 7240437 — intervention group
Group type: COMPARATOR
Intervention: Oxaprozin (1200 mg once a day)
Number of subjects: 16
Study 31325382 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-implant probing
Number of subjects: 65
Study 31325382 — intervention group
Group type: COMPARATOR
Intervention: Periodontal probing
Number of subjects: 65
Study 31325382 — intervention group
Group type: COMPARATOR
Intervention: Implant design (with/without platform switching)
Number of subjects: 65
Study 29954673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff-pressure pain stimulation (CuPS)
Number of subjects: 0
Study 29954673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CoPT)
Number of subjects: 0
Study 29954673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermode-based cold painful stimulation (TCPS)
Number of subjects: 0
Study 27467084 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic career coaching intervention
Number of subjects: 24
Study 24550145 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint attention intervention
Number of subjects: 40
Study 24550145 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic play intervention
Number of subjects: 40
Study 24550145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 22682555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg)
Number of subjects: 119
Study 22682555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 119
Study 20827920 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridectomy performed on 22 eyes in group 1 (subgroup 1A)
Number of subjects: 68
Study 20827920 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridectomy performed on 12 eyes in group 2 (subgroup 2A)
Number of subjects: 68
Study 20827920 — intervention group
Group type: COMPARATOR
Intervention: No iridectomy in 22 eyes in group 1 (subgroup 1B)
Number of subjects: 68
Study 20827920 — intervention group
Group type: COMPARATOR
Intervention: No iridectomy in 12 eyes in group 2 (subgroup 2B)
Number of subjects: 68
Study 18822976 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) in the no-blocking group
Number of subjects: 50
Study 18822976 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6) in the blocking group
Number of subjects: 50
Study 15850497 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of oral glucosamine sulphate (GS)
Number of subjects: 0
Study 15850497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12456918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder augmentation using intestinal segments in myelomeningocele patients
Number of subjects: 33
Study 12456918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder augmentation in bladder exstrophy patients
Number of subjects: 33
Study 12456918 — intervention group
Group type: COMPARATOR
Intervention: Non-augmented myelomeningocele patients
Number of subjects: 33
Study 12456918 — intervention group
Group type: COMPARATOR
Intervention: Non-augmented bladder exstrophy patients
Number of subjects: 33
Study 12456918 — intervention group
Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 33
Study 10839045 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of educative‐supportive system of care and behavior modification (Condition 1)
Number of subjects: 20
Study 10839045 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Condition 2)
Number of subjects: 20
Study 8743243 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD-high aggressive boys
Number of subjects: 45
Study 8743243 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported goals of defiance and cooperation
Number of subjects: 45
Study 8743243 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer-inferred goals
Number of subjects: 45
Study 1685504 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene coveralls
Number of subjects: 0
Study 1685504 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical clothing
Number of subjects: 0
Study 1685504 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic
Number of subjects: 0
Study 1685504 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available non‐woven swabs
Number of subjects: 0
Study 6138060 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 12
Study 6138060 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg midazolam
Number of subjects: 12
Study 6138060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31857780 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bismuth-containing quadruple therapy (mBCQT) for 2 weeks
Number of subjects: 136
Study 31857780 — intervention group
Group type: COMPARATOR
Intervention: Concomitant therapy (CT) for 2 weeks
Number of subjects: 136
Study 31857780 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bismuth-containing quadruple therapy (mBCQT)
Number of subjects: 136
Study 31857780 — intervention group
Group type: COMPARATOR
Intervention: Concomitant therapy (CT)
Number of subjects: 136
Study 29901652 — intervention group
Group type: EXPERIMENTAL
Intervention: PSTPVB + IV PCA
Number of subjects: 56
Study 29901652 — intervention group
Group type: COMPARATOR
Intervention: IV PCA
Number of subjects: 56
Study 25395221 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy (IH-CBT) plus home visiting (n = 47)
Number of subjects: 93
Study 25395221 — intervention group
Group type: COMPARATOR
Intervention: Standard home visiting (SHV; n = 46)
Number of subjects: 93
Study 24268907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid gel
Number of subjects: 0
Study 24268907 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 22166954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucromalt (30 g)
Number of subjects: 10
Study 22166954 — intervention group
Group type: COMPARATOR
Intervention: Inulin (15 g)
Number of subjects: 10
Study 21217832 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (300 mg/day)
Number of subjects: 36
Study 21217832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17388715 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 69
Study 16137837 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol suppositories
Number of subjects: 100
Study 16137837 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 100
Study 14656921 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ACEI) group, n=19
Number of subjects: 31
Study 14656921 — intervention group
Group type: COMPARATOR
Intervention: No-ACEI group, n=12
Number of subjects: 31
Study 10626195 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (500 mg/m2/day by continuous intravenous infusion for 5 days) combined with cisplatin (80 mg/m2 intravenously on the 1st day)
Number of subjects: 37
Study 7592207 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual induction (RI) by road over 4 days to 3,500 m
Number of subjects: 2
Study 7592207 — intervention group
Group type: COMPARATOR
Intervention: Acute induction (AI) by aircraft to 3,500 m in 1 hour
Number of subjects: 2
Study 7592207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RI and AI) at 4,200 m
Number of subjects: 2
Study 2041004 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.01 mg/kg)
Number of subjects: 0
Study 2041004 — intervention group
Group type: COMPARATOR
Intervention: Doxapram (1 mg/kg)
Number of subjects: 0
Study 2041004 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 7368100 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFT (Cytoxan, methotrexate, and 5‐fluorouracil plus tamoxifen)
Number of subjects: 0
Study 7368100 — intervention group
Group type: COMPARATOR
Intervention: CMF (Cytoxan, methotrexate, and 5‐fluorouracil)
Number of subjects: 0
Study 29481504 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow concentrates and CGF
Number of subjects: 20
Study 29481504 — intervention group
Group type: COMPARATOR
Intervention: Control (no grafting)
Number of subjects: 20
Study 27117749 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 965
Study 27117749 — intervention group
Group type: COMPARATOR
Intervention: Conventional White Light Imaging (WL)
Number of subjects: 965
Study 24659140 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial weight supported treadmill gait training (PWSTT)
Number of subjects: 60
Study 24659140 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional gait training (CGT)
Number of subjects: 60
Study 24659140 — intervention group
Group type: COMPARATOR
Intervention: Control group (stable medication only)
Number of subjects: 60
Study 23366357 — intervention group
Group type: EXPERIMENTAL
Intervention: Real RF-EMF exposure (WCDMA module, 24 dBm, 1950 MHz, 1.57 W/kg for 32 min)
Number of subjects: 37
Study 23366357 — intervention group
Group type: COMPARATOR
Intervention: Sham RF-EMF exposure
Number of subjects: 37
Study 20022708 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic cryopreserved keratinocytes
Number of subjects: 27
Study 20022708 — intervention group
Group type: COMPARATOR
Intervention: Split skin grafts
Number of subjects: 27
Study 18345521 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix acetate 0.25 mg) administered when follicles reached > or =14 mm
Number of subjects: 93
Study 18345521 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (leuprolide acetate) in a long protocol
Number of subjects: 93
Study 15820460 — intervention group
Group type: EXPERIMENTAL
Intervention: SP‐based seminar
Number of subjects: 31
Study 15820460 — intervention group
Group type: COMPARATOR
Intervention: Traditional seminar
Number of subjects: 31
Study 12453982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT)
Number of subjects: 62
Study 12453982 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 10027580 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (tinzaparin) for 3 weeks
Number of subjects: 45
Study 10027580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7746914 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 1600 micrograms day-1 for 6 weeks
Number of subjects: 12
Study 7746914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1799911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitro-Dur Transdermal Infusion System
Number of subjects: 72
Study 1799911 — intervention group
Group type: COMPARATOR
Intervention: Transderm-Nitro Transdermal Therapeutic System
Number of subjects: 72
Study 1799911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitro-Dur
Number of subjects: 72
Study 6230209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate - 50 mg b.i.d.
Number of subjects: 9
Study 6230209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6230209 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 9
Study 31734605 — intervention group
Group type: EXPERIMENTAL
Intervention: rs9939049 in CDH1
Number of subjects: 1948
Study 30770517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) for 1 year
Number of subjects: 148
Study 29246960 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐3 ethyl‐ester (1.86 g of eicosapentaenoic acid and 1.5 g of docosahexaenoic acid daily)
Number of subjects: 285
Study 29246960 — intervention group
Group type: COMPARATOR
Intervention: Control (no omega-3)
Number of subjects: 285
Study 26036082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic electrical neurostimulation (DENS)
Number of subjects: 0
Study 26036082 — intervention group
Group type: COMPARATOR
Intervention: Standard combined treatment (including pharmacotherapy, massage, and therapeutic physical culture exercises)
Number of subjects: 0
Study 23143710 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-mix (1.8 ml 2% lignocaine with 1:200,000 epinephrine + 1 ml of 4 mg dexamethasone)
Number of subjects: 20
Study 23143710 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine with 1:200,000 epinephrine
Number of subjects: 20
Study 22186855 — intervention group
Group type: EXPERIMENTAL
Intervention: Only children
Number of subjects: 200